Global Renal Biomarker Market Research and Forecast 2018-2023

Global Renal Biomarker Market, Size, Share, Market Intelligence, Company Profiles, Market Trends, Strategy, Analysis, Forecast 2018-2023

Kidney diseases or renal diseases is one of the major causes of deaths across the globe. The incidence of the renal diseases, particularly in geriatric population is rising rapidly owing to better life expectancy due to improvements in medical systems. Diabetes and high blood pressure are the leading cause of renal disease. A biomarker is an indicator of a specific biological state, relevant to the risk for, the presence of, or the stage of any disease. Biomarkers are clinically used for various purpose such as screening, diagnosing, or monitoring the activity of any diseases. in addition, it can guide molecularly targeted therapy or assess therapeutic response. Research and development activities undertaken by the biomarker manufacturers have led to identification of novel renal biomarkers for delivering better diagnostic accuracy and for improving patient outcomes. Major factors contributing to the growth of the global renal biomarker market include innovation in the biomarker for improving lives of the people with kidney diseases. In addition, increasing diabetic patient pool and rising number of patients with high blood pressure coupled with aging population as well as increasing prevalence of various kidney related disease are also contributing significantly in the growth of renal biomarker market. However, lack of regulatory and reimbursement systems, and limited market capabilities in the under-developed markets hinders the growth of the market.

Browse full report at: https://www.omrglobal.com/industry-reports/renal-biomarker-market/

The renal biomarker market can be segmented on the basis of, type, diagnostic technique and end users. Based on the type, the renal biomarker market is bifurcated as diagnostic biomarkers, prognostic biomarkers, predictive biomarkers, and pharmacodynamic biomarkers. On the basis of diagnostic technique, the market is diversified as ELISA, colorimetric assay, liquid chromatography – mass spectrometry and particle enhanced turbidimetric immunoassay. Based on the end users, the renal biomarker market is sub-divided as hospitals, diagnostic labs and research centers. Among the diagnostic technique, ELISA is expected to hold the largest market share. In addition, diagnostic labs among the end users is projected to be dominating segment.

The global renal biomarker market is further analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. The North America is expected to be dominating in the renal biomarker market owing to the presence of high quality healthcare infrastructure. In addition, prevalence rate of renal diseases is high in this region. Europe is another significant market and holds a considerable market share in the global renal biomarker market.

Some of the key players operating in the global renal biomarker market are Abbott Laboratories Inc., Astute Medical Inc., Beckman Coulter Inc., Novartis AG, Roche Diagnostics and several others. In order to sustain in the competitive market, these players adopt various strategies such as merger & acquisitions, expansions, joint ventures and product development and partnership and collaboration. For instance, Bristol-Myers Squibb in January 2017 along with the GeneCentric Diagnostics entered into a Biomarker Research Collaboration. The collaboration is to explore if the Cancer Subtype Platform (CSP) of the GeneCentric is capable of identifying translational biomarkers for Opdivo. OPDIVO (nivolumab) is used as an indication for the treatment of advanced renal cell carcinoma (RCC) patients who have received prior anti-angiogenic therapy.

For related reports please visit: Biotechnology Industry